Pembrolizumab for metastatic melanoma in a renal allograft recipient with subsequent graft rejection and treatment response failure: a case report

BACKGROUND: Transplant patients were excluded from the pivotal phase III trials of checkpoint inhibitors in metastatic melanoma. The efficacy and toxicity profiles of checkpoint inhibitors in this cohort of patients are not well described. To the best of our knowledge, this is the first case report...

Descripción completa

Detalles Bibliográficos
Autores principales: Kwatra, Vineet, Karanth, Narayan V., Priyadarshana, Kelum, Charakidis, Michail
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5357565/
https://www.ncbi.nlm.nih.gov/pubmed/28315636
http://dx.doi.org/10.1186/s13256-017-1229-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5357565/
https://www.ncbi.nlm.nih.gov/pubmed/28315636
http://dx.doi.org/10.1186/s13256-017-1229-z

Ejemplares similares